Oak Thistle LLC Purchases 8,490 Shares of Amedisys, Inc. (NASDAQ:AMED)

Oak Thistle LLC raised its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 121.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,454 shares of the health services provider's stock after acquiring an additional 8,490 shares during the quarter. Oak Thistle LLC's holdings in Amedisys were worth $1,432,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Cerity Partners LLC bought a new position in shares of Amedisys in the first quarter worth approximately $463,000. Trexquant Investment LP raised its position in Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after acquiring an additional 81,532 shares during the period. Fifth Third Bancorp raised its position in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock worth $32,000 after acquiring an additional 141 shares during the period. Teacher Retirement System of Texas bought a new position in Amedisys in the first quarter worth approximately $817,000. Finally, M&T Bank Corp purchased a new stake in shares of Amedisys in the first quarter worth $315,000. Hedge funds and other institutional investors own 94.36% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMED shares. Wall Street Zen cut shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Royal Bank Of Canada reissued an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th.

Amedisys Price Performance

AMED traded up $0.11 during trading on Friday, hitting $97.94. 417,520 shares of the company traded hands, compared to its average volume of 400,474. The company has a market cap of $3.21 billion, a PE ratio of 36.14, a P/E/G ratio of 1.33 and a beta of 0.94. The stock's 50-day simple moving average is $96.34 and its two-hundred day simple moving average is $93.97. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. Amedisys's quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $1.03 earnings per share. As a group, sell-side analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.